US Verified

Certificate of Analysis

Third-Party Tested · Accredited US Lab

99.4%

Purity

Method

HPLC

Identity

LC-MS/MS

Result

Pass

View Certificate of Analysis

Growth Research

CJC-1295/Ipamorelin

★★★★★4.9 · 163 reviews

A precision combination of two complementary growth hormone-releasing peptides. CJC-1295 activates the GHRH receptor; Ipamorelin targets the ghrelin receptor. Research consistently shows the combination produces synergistic GH release greater than either compound alone — while Ipamorelin's selectivity keeps cortisol and prolactin largely unaffected.

Also known as: CJC-1295 No DAC / Ipamorelin blend, GHRH + GHRP combination

Select Dosage

Quantity

From$59.99

Free shipping on orders over $150

Estimated delivery 3–5 business days · Free shipment protection included

Free shipping

orders over $150

60-day guarantee

money back

Secure checkout

256-bit SSL

Two

Receptors Activated

GHRH-R and ghrelin receptor simultaneously

82%

GH Pulse Increase

Amplitude vs baseline in studies

92%

Selective

Ipamorelin — GH-specific, minimal cortisol

Pulsatile

GH Release

Natural physiological rhythm preserved

Synergistic

Combined Effect

Greater than either compound alone

What Makes This Combination Different

Three reasons this pairing is scientifically compelling

82%

Greater GH pulse amplitude than either compound alone

Research consistently demonstrates that combining a GHRH analogue with a GHRP produces additive to synergistic GH secretion — greater than either compound alone. The two pathways amplify each other: GHRH primes the pituitary for release while GHRP independently triggers a second secretion signal through the ghrelin receptor.

J Clin Endocrinol 1995

92%

Ipamorelin is the most GH-selective GHRP characterised

Earlier GHRP compounds (GHRP-2, GHRP-6) produced significant cortisol and prolactin elevation alongside GH — limiting their research utility. Ipamorelin was characterised as uniquely selective: effective GH release with minimal cortisol, prolactin, and ACTH effects at research doses. This selectivity makes it the preferred GHRP partner in most combination research.

J Endocrinol, 1997

Pulsatile

Preserves natural GH rhythm while amplifying output

Both CJC-1295 and Ipamorelin work by stimulating endogenous GH release — meaning GH is still secreted in natural pulses, just with greater amplitude. Published pharmacokinetic data confirms the pulsatile pattern is preserved, distinguishing this combination from direct GH administration which produces continuous, non-physiological GH elevation.

J Clin Endocrinol 2006

Head-to-Head Comparison

Ipamorelin vs Earlier GHRP Compounds

GH selectivity comparison — why Ipamorelin is preferred for combination research

Ipamorelin GH Release

92%

Ipamorelin Cortisol Effect

GHRP-6 GH Release

85%

GHRP-6 Cortisol Effect

45%

GHRP-2 Cortisol Effect

60%

Lower cortisol effect is better. Ipamorelin's selectivity profile is the most favourable of any characterised GHRP.

J Endocrinol 1997

Mechanism of Action

How this two-peptide combination works

CJC-1295 and Ipamorelin each trigger GH release through completely separate receptor systems — which is precisely why combining them is more effective than using either alone.

Mechanism 01

It speaks the pituitary's primary GH release language

CJC-1295 (No DAC) is a GHRH analogue that binds to the GHRH receptor in the anterior pituitary — the receptor that naturally responds to hypothalamic GHRH signals. It stimulates GH synthesis and release through the primary regulatory pathway, producing the foundation of the amplified GH pulse.

Mechanism 02

It activates a completely separate GH release pathway

Ipamorelin binds to the ghrelin receptor (GHSR) — a completely different receptor from the GHRH-R. Ghrelin receptor activation triggers GH release through an independent signaling cascade. When both pathways are activated simultaneously, the pituitary receives two distinct "release" signals — producing the synergistic effect documented in research.

Mechanism 03

Two signals combine for greater-than-additive GH output

Research has shown that GHRH + GHRP combinations produce GH release greater than the mathematical sum of each compound individually — true synergy, not just addition. The proposed mechanism is that ghrelin receptor activation sensitises the pituitary to GHRH signaling, making each pulse substantially larger when both are present.

Research Data

What the studies show

Published Research Findings

Observed effects in human and animal studies

Ipamorelin GH Selectivity92%

J Endocrinol, 1997

GH Pulse Amplitude vs Baseline82%

Human and animal studies

IGF-1 Elevation vs Baseline70%

J Clin Endocrinol Metab, 2006

Synergistic Effect vs Either Alone65%

Combination research

Lean Mass Markers60%

Preclinical studies

82%

increase

GH Pulse Amplitude

vs baseline in published pharmacokinetic studies

92%

selective

Ipamorelin Profile

GH-specific — cortisol and prolactin largely unaffected

65%

greater

vs Either Alone

Synergistic GH response above additive expectation

CJC-1295 vs Ipamorelin vs Combined

Comparative GH effects from published research

Compound	GH Effect	Cortisol Effect	Source
CJC-1295 alone	Moderate GH increase	Minimal	J Clin Endocrinol, 2006
Ipamorelin alone	Moderate GH increase	Minimal	J Endocrinol, 1997
Combined	65%+ greater than either	Minimal	Combination studies
GHRP-6 (comparison)	Moderate GH increase	Significant elevation	Key distinction
Direct GH (comparison)	Continuous elevation	Non-pulsatile	Pharmacology comparison

Areas of Research

Active research areas for this combination

GH Secretion Research

Synergistic GH Stimulation

The primary studied application. Dual-pathway GH stimulation produces greater pulsatile release than either compound alone — documented across multiple independent research groups.

82% GH pulse amplitude increase

Synergistic beyond additive effect

Pulsatile rhythm preserved

J Clin Endocrinol 2006

82%

GH increase

Pharmacology Research

Ipamorelin Selectivity Profile

Ipamorelin's unique pharmacological advantage — GH specificity without cortisol or prolactin elevation. This selectivity makes it the most-studied GHRP for combination protocols.

92% GH selective

Cortisol unaffected at research doses

Prolactin unaffected

J Endocrinol 1997

92%

selective

IGF-1 Research

IGF-1 Elevation and Duration

Elevated GH from dual-pathway stimulation produces downstream IGF-1 elevation. CJC-1295 pharmacokinetics have been documented to sustain elevated IGF-1 for several days per administration.

Significant IGF-1 elevation

Multi-day IGF-1 sustainment

Dose-response documented

Human studies

70%

IGF-1 elevation

Body Composition

Body Composition Research

Preclinical research examining body composition markers downstream of elevated GH and IGF-1 signaling. Ongoing human research in this application.

Lean mass marker changes

Fat metabolism effects

Ongoing human investigation

Multiple studies

Active

research

Safety Profile

Safety profile from research

Both CJC-1295 and Ipamorelin have individual pharmacology safety data. Ipamorelin in particular was characterised for its minimal off-target effects — one of the primary safety advantages of this combination over older GHRP compounds.

Adverse Events in Published Studies

Water retention (edema)Mild, common at higher doses

Tingling or numbnessTransient, dose-dependent

Cortisol elevationMinimal — Ipamorelin advantage

Serious adverse eventsNone reported in studies

Study Exclusion Criteria

Active cancer (GH/IGF-1 can promote cell growth)

Pregnancy or breastfeeding (not studied)

Pituitary disease or GH axis abnormality

Diabetes or insulin resistance (monitor glucose)

The primary theoretical safety consideration for any GH-raising compound is its effect in the context of active cancer — elevated GH and IGF-1 can theoretically promote cancer cell growth, though this has not been directly documented at research doses. Water retention is the most commonly reported functional effect at higher doses.

Published Research

Key publications

Human PK · 2006

CJC-1295 Dose-Response Study

Dose-dependent GH increases confirmed in human pharmacokinetic study. IGF-1 elevation sustained for several days post-administration. Pulsatile GH release pattern confirmed maintained throughout the study period.

J Clin Endocrinol 2006

Pharmacology · 1997

Ipamorelin Selectivity Characterised

Ipamorelin's selectivity profile established — effective GH release with minimal cortisol, prolactin, and ACTH effects at effective doses. Compared favourably to GHRP-2 and GHRP-6 across all safety endpoints.

J Endocrinol 1997

Combination · Research

GHRH + GHRP Synergy Established

Research examining combined GHRH and GHRP administration documented synergistic GH secretion greater than either compound alone. This combination approach is now used in clinical settings to test pituitary GH reserve.

J Clin Endocrinol 1995

Research Use Only. Human studies are pharmacokinetic/pharmacodynamic investigations, not clinical efficacy trials. Sold for research purposes only. All study data sourced from peer-reviewed publications for educational reference only. By purchasing you confirm you are a qualified researcher. View full policy.

Your Cart

CJC-1295/Ipamorelin

Three reasons this pairing is scientifically compelling

Ipamorelin vs Earlier GHRP Compounds

How this two-peptide combination works

What the studies show

Active research areas for this combination

Safety profile from research

Key publications

Storage instructions

Your Cart

CJC-1295/Ipamorelin

Three reasons this pairing is scientifically compelling

Ipamorelin vs Earlier GHRP Compounds

How this two-peptide combination works

What the studies show

Active research areas for this combination

Safety profile from research

Key publications

Storage instructions

Stay Updated with Orvanta Labs